Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vital KSK HoldingsTSE:3151 +1.39%64 EV-to-EBITDA is 4.03 as of Aug. 14, 2026, which is 26% below its 10-year median of 5.43. GuruFocus rates TSE:3151 with a GF Score™ of 64/100 and a GF Value™ of 円1,330.04 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 98 Medical Distribution companies, Vital KSK Holdings ranks better than 85.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vital KSK Holdings's enterprise value is 円61,471 Mil.
Vital KSK Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円15,241 Mil. Therefore, Vital KSK Holdings's EV-to-EBITDA for today is 4.03.
The historical rank and industry rank for Vital KSK Holdings's EV-to-EBITDA or its related term are showing as below:
TSE:3151'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.12 Med: 5.43 Max: 17.96
Current: 4.03
During the past 13 years, the highest EV-to-EBITDA of Vital KSK Holdings was 17.96. The lowest was 2.12. And the median was 5.43.
TSE:3151's EV-to-EBITDA is ranked better than 85.71% of 98
companies
in the Medical Distribution industry
Industry Median: 8.44
vs TSE:3151: 4.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vital KSK Holdings's PE Ratio (TTM) for today is calculated as:
Vital KSK Holdings's share price for today is 円1605.00.
Vital KSK Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円145.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vital KSK Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3151 vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, Vital KSK Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vital KSK Holdings EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Vital KSK Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vital KSK Holdings's EV-to-EBITDA falls into.
Vital KSK Holdings's current Enterprise Value is 円61,471 Mil.
Vital KSK Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円15,241 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vital KSK Holdings (TSE:3151) has a EV-to-EBITDA of 4.03 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vital KSK Holdings. This is 26% below median its historical median of 5.43. Over the past decade, Vital KSK Holdings' EV-to-EBITDA has ranged from 2.12 to 17.96. According to the industry distribution chart, Vital KSK Holdings ranks #14 out of 98 companies in the Medical Distribution industry, placing it in the top 14.3%.
Is Vital KSK Holdings' EV-to-EBITDA too high?
Vital KSK Holdings' current EV-to-EBITDA of 4.03 is 26% below median its 10-year median of 5.43. Over the past 10 years, this metric has ranged from a low of 2.12 to a high of 17.96. The Medical Distribution industry median EV-to-EBITDA is 8.44. Vital KSK Holdings' value of 4.03 is 52.3% below this industry median. Based on the distribution chart, Vital KSK Holdings ranks #14 out of 98 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Vital KSK Holdings has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vital KSK Holdings' EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Vital KSK Holdings ranks #14 out of 98 companies for EV-to-EBITDA. This places Vital KSK Holdings in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 8.44. Vital KSK Holdings' value of 4.03 is 52.3% below this benchmark. Historically, Vital KSK Holdings' own EV-to-EBITDA has ranged from 2.12 to 17.96 over the past decade. While the company's 10-year median is 5.43 vs. the industry median of 8.44, Vital KSK Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.44, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vital KSK Holdings's current EV-to-EBITDA of 4.03 is 52.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vital KSK Holdings. For the Medical Distribution industry, the median EV-to-EBITDA is 8.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vital KSK Holdings's current EV-to-EBITDA is 4.03, which is 26% below median its own 10-year median of 5.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vital KSK Holdings stock overvalued right now?
Based on GuruFocus' analysis, Vital KSK Holdings (TSE:3151) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,330.04, compared to a current price of 円1,605.00 — trading 20.7% above its estimated fair value. The current EV-to-EBITDA is 4.03, which is 26% below median its 10-year median of 5.43 and 52.3% below the Medical Distribution industry median of 8.44. Vital KSK Holdings' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vital KSK Holdings (TSE:3151), the current EV-to-EBITDA is 4.03 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vital KSK Holdings (TSE:3151) Overvalued in 2026?
Based on GuruFocus' analysis, Vital KSK Holdings stock appears to be overvalued.
The current stock price of 円1,605.00 is trading 20.7% above its estimated GF Value™ of 円1,330.04.
GuruFocus considers Vital KSK Holdings to be Modestly Overvalued.
Key valuation signals for TSE:3151:
EV-to-EBITDA: 4.03 (26% below median its 10-year median of 5.43)
GF Value™: 円1,330.04 vs. price of 円1,605.00 (20.7% above fair value)
Industry Position: 52.3% below the Medical Distribution median (#14 of 98)
No single metric tells the full story. See the TSE:3151 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vital KSK Holdings Inc engaged in the wholesale and retail of pharmaceutical products. It operates through the Pharmaceutical Wholesale and Other segments. The Pharmaceutical Wholesale segment sells medicines, diagnostics, and medical devices to hospitals, medical institutions, and health practitioners. The Other segment includes retail of pharmaceutical products, wholesale of agrochemical and veterinary drugs, transportation, nursing care services, and medical consultancies. All the business activity of the group is primarily functioned through Japan and distributes its product within the Korean and to overseas market.
64GF Score
Get the complete analysis for TSE:3151
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3151 has been successfully added to your 
